Search results for "Large cell"

showing 10 items of 20 documents

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer p…

2011

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the anti-angiogenic effects and toxicity of a newest bevacizumab-based combination with fractioned cisplatin and daily oral etoposide. We designed a phase II trial to evaluate in advanced NSCLC patients the antitumor activity and the safety of this novel regimen. In particular, 45 patients (36 males and 9 females), with a mean age of 54 years, an ECOG ≤2, stage III B/IV and NSCLC (28 adenocarcinomas, 11 squamous-cell carcinomas, 2 large-cell carcin…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsBevacizumabDose-dense chemotherapyAdenocarcinomaNSCLCAntibodies Monoclonal HumanizedDrug Administration ScheduleInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsDose/dense-metronomic-chemotherapymedicineHumansLung cancerAgedEtoposideNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerAntibodies MonoclonalmPEBev regimenMiddle Agedmedicine.diseaseVEGFBevacizumabRegimenOncologyToxicityCarcinoma Squamous CellMolecular MedicineEvery Three WeeksCarcinoma Large CellFemaleCisplatinbusinessmedicine.drugCancer biologytherapy
researchProduct

Molecular Classification of Pesticides Including Persistent Organic Pollutants, Phenylurea and Sulphonylurea Herbicides

2014

Pesticide residues in wine were analyzed by liquid chromatography–tandem mass spectrometry. Retentions are modelled by structure–property relationships. Bioplastic evolution is an evolutionary perspective conjugating effect of acquired characters and evolutionary indeterminacy–morphological determination–natural selection principles; its application to design co-ordination index barely improves correlations. Fractal dimensions and partition coefficient differentiate pesticides. Classification algorithms are based on information entropy and its production. Pesticides allow a structural classification by nonplanarity, and number of O, S, N and Cl atoms and cycles; different behaviours depend …

Periodic table (large cells)periodic law; periodic property; periodic table; molecular classificationperiodic tablePharmaceutical ScienceWineFractal dimensionArticleAnalytical Chemistrylcsh:QD241-441lcsh:Organic chemistryTandem Mass SpectrometryDrug DiscoveryPesticidesPhysical and Theoretical ChemistryPollutantChromatographyMolecular Structuremolecular classificationChemistryOrganic ChemistryPesticide Residuesperiodic lawPesticideperiodic propertyStatistical classificationSulfonylurea CompoundsCategorizationChemistry (miscellaneous)Principal component analysisMolecular MedicineBiological systemCombinatorial explosionChromatography LiquidMolecules; Volume 19; Issue 6; Pages: 7388-7414
researchProduct

Primary multifocal anaplastic large cell lymphoma with eyelid involvement: a case report

2019

ABSTRACT Ocular adnexal involvement in CD30+ lymphoproliferative disorders is rare. We report the case of a 73-year-old woman with a relapsing primary cutaneous anaplastic large cell lymphoma on her eyelid. A systemic extension study excluded extracutaneous involvement. Systemic chemotherapy resulted in an optimal response, with complete regression of the cutaneous lesions. There has been no recurrence during the 2 years of follow-up. RESUMO O acometimento ocular adicional nos distúrbios linfoproliferativos CD30+ é raro. Relatamos o caso de uma mulher de 73 anos com linfoma de grandes células anaplásicas primárias recidivantes em sua pálpebra. A avaliação sistêmica excluiu envolvimento extr…

Pathologymedicine.medical_specialtyCD30Neoplasias palpebraisLymphoproliferative disordersPrimary cutaneous anaplastic large cell lymphomalcsh:OphthalmologyComplete regressionmedicineLinfoma anaplásico cutâneo primário de células grandesAnaplastic large-cell lymphomaLymphoma primary cutaneous anaplastic large cellCase reportsRelatos de casosSystemic chemotherapybusiness.industryGeneral MedicineLymphoma T-cell cutaneousEyelid Neoplasmmedicine.diseaseOphthalmologymedicine.anatomical_structurelcsh:RE1-994Linfoma cutâneo de células TEyelidbusinessEyelid neoplasms
researchProduct

Ultrastructure of vascular neoplasms

1982

Summary The vascular tumors are morphologically recognized by their ability to configurate complete or atypical angiomatous structures. Based on our personal experience of 42 cases of benign and malignant angiomatous tumors, we discussed several aspects of their histogenesis and its morphology when studied with transmission and scanning electron microscopy. Therefore, a survey of the normal histology was developed based not only on normal adult histological structures but also on reparative tissues, as in chronic inflammatory reactions of the gingival mucosa, regenerative tissue of wounds and in chronic osteomyelitis. Supported by morphological arguments, we postulate the existence of sever…

HemangiopericytomaPathologymedicine.medical_specialtyAngiogenesisLarge cellCell BiologyBiologymedicine.diseasePathology and Forensic MedicineHemangioendotheliomaEndothelial stem cellAngiomaVascular NeoplasmmedicineSarcomaPathology - Research and Practice
researchProduct

Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway gene…

2016

Oncologymedicine.medical_specialtysocs1030230 surgerymedicine.disease_causestat303 medical and health sciencesDNMT3A; SOCS1; STAT3; TP53; breast implant-associated anaplastic large-cell lymphoma; somatic mutations0302 clinical medicineInternal medicinemedicineAnaplastic lymphoma kinasebreast implant-associated anaplastic large-cell lymphomaSTAT3Anaplastic large-cell lymphomaMutationbiologySuppressor of cytokine signaling 1hematologyLarge cellJAK-STAT signaling pathwaybreast implantâ associated anaplastic large-cell lymphomatp53medicine.diseaseLymphomabreast implant-associated anaplastic large-cell lymphoma; dnmt3a; socs1; somatic mutations; stat3; tp53; hematology030220 oncology & carcinogenesisdnmt3aCancer researchbiology.proteinsomatic mutationsbreast implant–associated anaplastic large-cell lymphoma; DNMT3A; SOCS1; somatic mutations; STAT3; TP53; Hematology
researchProduct

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Adva…

2012

INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here. METHODS:: QoL was assessed at baseline and every 3 weeks during first-line, using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and QLQ-lung cancer specific module (LC13). Mean changes from baseline within arms …

OncologyMaleerlotinibLung NeoplasmsHealth-related quality of lifeNSCLCchemotherapyDeoxycytidinelaw.inventionRandomized controlled trialQuality of lifelawCarcinoma Non-Small-Cell LungSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsSurveys and QuestionnaireQuality of life analysis of TORCHErlotinib HydrochloridePrognosishumanitiesOncologyResearch DesignAdvanced non–small-cell lung cancerCarcinoma Squamous CellFemaleErlotinibRandomized trialmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiEGFRFirst-line treatmentfirst-line erlotinibsecond-line cisplatin/gemcitabine chemotherapyAdenocarcinomaNOFollow-Up StudieErlotinib HydrochlorideInternal medicineadvanced non-small-cell lung cancermedicineHumansLung cancerAdvanced non-small-cell lung cancer; Chemotherapy; EGFR; Erlotinib; First-line treatment; Health-related quality of life; Randomized trialQuality of life analysis of TORCH first-line erlotinib second-line cisplatin/gemcitabine chemotherapy advanced non-small-cell lung cancer.AgedNeoplasm StagingSalvage TherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryQuestionnaireCancerQuinazolinemedicine.diseaseInterim analysisGemcitabineGemcitabineSurgeryLung Neoplasmquality of lifeQuinazolinesCarcinoma Large CellCisplatinNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials

2021

BACKGROUND Ten-year survival rates in mycosis fungoides (MF) broadly varies, however, there is no standardized prognostic index available. This is presumably due to low prevalence, heterogeneity, and diagnostic challenges in MF. Recent studies have focused on identifying objective prognostic indices by using different parameters for survival determinants. The Cutaneous Lymphoma International Prognostic Index (CLIPI) and the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) represent prototypical studies that identify prognostic factors, seeking to improve management and outcomes in early-stage MF. Detecting these factors and stratifying MF patients according to their …

MaleOncologymedicine.medical_specialtySkin Neoplasms610 MedizinDermatologyDiseaseCutaneous lymphomaMycosis FungoidesInternational Prognostic IndexInternal medicine610 Medical sciencesmedicineHumansProspective StudiesStage (cooking)Neoplasm StagingMycosis fungoidesbusiness.industryLarge cellPrognosismedicine.diseaseLymphomaT-stageFemalebusiness
researchProduct

"Pure" large cell neuroendocrine carcinoma of the gallbladder. Report of a case and review of the literature

2016

Primary Neuroendocrine Tumours (NETs) of the gallbladder are rare. Among all NETs of the gallbladder, large cell neuroendocrine carcinoma (LCNEC) is exceedingly rare. In most of the cases LCNECs are combined with other histological components. We reviewed clinical presentation and management of all patients with "pure" LCNEC from published literature since the first case was published in 2000, as well as one patient from our experience. Only 7 cases of "pure" LCNEC has been described in the last 15 years, our case is the eighth. The diagnosis of gallbladder NETs is rarely made preoperatively since the presentation generally consists of non-specific symptoms including upper abdominal pain, d…

medicine.medical_specialtyCarcinoma; Gallbladder; Large cell neuroendocrine carcinoma; Neuroendocrine carcinoma; Neuroendocrine tumours; SurgeryGallbladder Neuroendocrine Carcinomamedicine.medical_treatmentGallstonesAdenocarcinomaNeuroendocrine tumorsSettore MED/08 - Anatomia PatologicaDiagnosis Differential03 medical and health sciences0302 clinical medicineNeuroendocrine tumourmedicineCarcinomaHepatectomyHumansAgedIncidental Findingsbusiness.industryLarge cell neuroendocrine carcinomaGallbladderGeneral surgeryLiver NeoplasmsCarcinomaGallbladderGeneral MedicineGallstonesmedicine.diseaseCarcinoma NeuroendocrineNeuroendocrine TumorsSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureCholecystectomy Laparoscopic030220 oncology & carcinogenesisNeuroendocrine carcinomaCarcinoma Large CellFemaleGallbladder Neoplasms030211 gastroenterology & hepatologySurgeryCholecystectomyRadiologyGallbladder NeoplasmDifferential diagnosisbusiness
researchProduct

Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres

1995

Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA2-L2. As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and s…

AdultMaleCD30+ HODGKINS-RELATED LYMPHOMACancer Researchmedicine.medical_specialtyPathologyAdolescentCD30CHOPGastroenterologyExtranodal Diseaseimmune system diseaseshemic and lymphatic diseasesInternal medicineInduction therapyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesAnaplastic large-cell lymphomaAgedbusiness.industryNON-HODGKINS LYMPHOMAMiddle Agedmedicine.diseaseLymphomaNon-Hodgkin's lymphomaSurvival RateRegimenTreatment OutcomeOncologyLymphoma Large-Cell AnaplasticFemaleANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+)AGGRESSIVE CHEMOTHERAPYANAPLASTIC LARGE CELL LYMPHOMA (CD30+/KI-1+); CD30+ HODGKINS-RELATED LYMPHOMA; NON-HODGKINS LYMPHOMA; AGGRESSIVE CHEMOTHERAPYbusinessFollow-Up StudiesEuropean Journal of Cancer
researchProduct

Superheavy-element research

1979

The existence of an island of relatively stable elements beyond the present Periodic Table has been predicted by theoretical extrapolations of nuclear properties. During the past 12 years vigorous efforts have been made to discover these superheavy elements in nature and to produce them by nuclear reactions.

Nuclear physicsNuclear reactionMultidisciplinaryPeriodic table (large cells)ChemistryElement (category theory)Superheavy ElementsNature
researchProduct